How much revenue did Veracyte generate this year?
Veracyte has achieved a revenue of 444.83 M USD this year.
Veracyte Revenue 2024
Veracyte Revenue
444.83 M USD
Ticker
VCYT
ISIN
US92337F1075
WKN
A1W7EA
In 2024, Veracyte's sales reached 444.83 M USD, a 23.2% difference from the 361.05 M USD sales recorded in the previous year.
The Veracyte Revenue history
| YEAR | REVENUE (undefined USD) | GROSS MARGIN (%) |
|---|---|---|
| 2026e | 540.57 | 45,90 |
| 2025e | 490.48 | 50,59 |
| 2024e | 444.83 | 55,78 |
| 2023 | 361.05 | 68,73 |
| 2022 | 296.5 | 65,77 |
| 2021 | 219.5 | 66,10 |
| 2020 | 117.5 | 64,68 |
| 2019 | 120.4 | 69,60 |
| 2018 | 92 | 64,02 |
| 2017 | 72 | 60,83 |
| 2016 | 65.1 | 60,83 |
| 2015 | 49.5 | 56,57 |
| 2014 | 38.2 | 56,54 |
| 2013 | 21.9 | 42,47 |
| 2012 | 11.6 | 34,48 |
| 2011 | 2.6 | -11,54 |
Veracyte Revenue, EBIT, Net Income US92337F1075 · A1W7EA
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Veracyte, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Veracyte from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Veracyte’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Veracyte. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Veracyte’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Veracyte’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Veracyte’s growth potential.
Veracyte Revenue, EBIT and net profit per share
| Date | Veracyte Revenue | Veracyte EBIT | Veracyte Net Income |
|---|---|---|---|
| 2026e | 540.57 M undefined | 58.22 M undefined | 52.36 M undefined |
| 2025e | 490.48 M undefined | 18.32 M undefined | 28.65 M undefined |
| 2024e | 444.83 M undefined | -3.51 M undefined | 11.86 M undefined |
| 2023 | 361.05 M undefined | -17.45 M undefined | -74.4 M undefined |
| 2022 | 296.5 M undefined | -37.8 M undefined | -36.6 M undefined |
| 2021 | 219.5 M undefined | -59.8 M undefined | -75.6 M undefined |
| 2020 | 117.5 M undefined | -35.4 M undefined | -34.9 M undefined |
| 2019 | 120.4 M undefined | -15.1 M undefined | -12.6 M undefined |
| 2018 | 92 M undefined | -22.2 M undefined | -23 M undefined |
| 2017 | 72 M undefined | -26.5 M undefined | -31 M undefined |
| 2016 | 65.1 M undefined | -28.8 M undefined | -31.4 M undefined |
| 2015 | 49.5 M undefined | -33.5 M undefined | -33.7 M undefined |
| 2014 | 38.2 M undefined | -29 M undefined | -29.4 M undefined |
| 2013 | 21.9 M undefined | -23.2 M undefined | -25.6 M undefined |
| 2012 | 11.6 M undefined | -18.9 M undefined | -18.6 M undefined |
| 2011 | 2.6 M undefined | -15.3 M undefined | -14.4 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2011 | 2.6 M USD | -15.3 M USD | -14.4 M USD |
| 2012 | 11.6 M USD | -18.9 M USD | -18.6 M USD |
| 2013 | 21.9 M USD | -23.2 M USD | -25.6 M USD |
| 2014 | 38.2 M USD | -29 M USD | -29.4 M USD |
| 2015 | 49.5 M USD | -33.5 M USD | -33.7 M USD |
| 2016 | 65.1 M USD | -28.8 M USD | -31.4 M USD |
| 2017 | 72 M USD | -26.5 M USD | -31 M USD |
| 2018 | 92 M USD | -22.2 M USD | -23 M USD |
| 2019 | 120.4 M USD | -15.1 M USD | -12.6 M USD |
| 2020 | 117.5 M USD | -35.4 M USD | -34.9 M USD |
| 2021 | 219.5 M USD | -59.8 M USD | -75.6 M USD |
| 2022 | 296.5 M USD | -37.8 M USD | -36.6 M USD |
| 2023 | 361.05 M USD | -17.45 M USD | -74.4 M USD |
| 2024e | 444.83 M USD | -3.51 M USD | 11.86 M USD |
| 2025e | 490.48 M USD | 18.32 M USD | 28.65 M USD |
| 2026e | 540.57 M USD | 58.22 M USD | 52.36 M USD |
Veracyte stock margins US92337F1075 · A1W7EA
The Veracyte margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Veracyte. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Veracyte.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Veracyte's sales revenue. A higher gross margin percentage indicates that the Veracyte retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Veracyte's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Veracyte's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Veracyte's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Veracyte. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Veracyte's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Veracyte Margin History
| Veracyte Gross margin | Veracyte Profit margin | Veracyte EBIT margin | Veracyte Profit margin |
|---|---|---|---|
| 2026e | 68.73 % | 10.77 % | 9.69 % |
| 2025e | 68.73 % | 3.73 % | 5.84 % |
| 2024e | 68.73 % | -0.79 % | 2.67 % |
| 2023 | 68.73 % | -4.83 % | -20.61 % |
| 2022 | 65.77 % | -12.75 % | -12.34 % |
| 2021 | 66.1 % | -27.24 % | -34.44 % |
| 2020 | 64.68 % | -30.13 % | -29.7 % |
| 2019 | 69.6 % | -12.54 % | -10.47 % |
| 2018 | 64.02 % | -24.13 % | -25 % |
| 2017 | 60.83 % | -36.81 % | -43.06 % |
| 2016 | 60.83 % | -44.24 % | -48.23 % |
| 2015 | 56.57 % | -67.68 % | -68.08 % |
| 2014 | 56.54 % | -75.92 % | -76.96 % |
| 2013 | 42.47 % | -105.94 % | -116.89 % |
| 2012 | 34.48 % | -162.93 % | -160.34 % |
| 2011 | -11.54 % | -588.46 % | -553.85 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2011 | -11.54 % | -588.46 % | -553.85 % |
| 2012 | 34.48 % | -162.93 % | -160.34 % |
| 2013 | 42.47 % | -105.94 % | -116.89 % |
| 2014 | 56.54 % | -75.92 % | -76.96 % |
| 2015 | 56.57 % | -67.68 % | -68.08 % |
| 2016 | 60.83 % | -44.24 % | -48.23 % |
| 2017 | 60.83 % | -36.81 % | -43.06 % |
| 2018 | 64.02 % | -24.13 % | -25 % |
| 2019 | 69.6 % | -12.54 % | -10.47 % |
| 2020 | 64.68 % | -30.13 % | -29.7 % |
| 2021 | 66.1 % | -27.24 % | -34.44 % |
| 2022 | 65.77 % | -12.75 % | -12.34 % |
| 2023 | 68.73 % | -4.83 % | -20.61 % |
| 2024e | 68.73 % | -0.79 % | 2.67 % |
| 2025e | 68.73 % | 3.73 % | 5.84 % |
| 2026e | 68.73 % | 10.77 % | 9.69 % |
Veracyte Aktienanalyse
What does Veracyte do?
Veracyte Inc is a company that specializes in the development and marketing of diagnostic tests for a wide range of diseases and disorders. The company was founded in 2008 and is headquartered in South San Francisco, California. The history of Veracyte Inc begins with the vision to help patients with better diagnostic options. The company has used its expertise in gene expression technology to develop tests that facilitate the diagnosis of diseases and disorders in various areas, such as cancer, thyroid diseases, and lung diseases. Veracyte Inc's business model is based on selling diagnostic tests to healthcare facilities, hospitals, doctors, and other medical institutions. The tests are performed by specially trained professionals and can provide a precise diagnosis that helps doctors plan individualized treatment. Veracyte Inc is divided into different divisions to offer the best and most precise test for each area. The divisions include cancer diagnosis, thyroid diagnostics, lung diagnostics, and other areas of gene expression technology. In cancer diagnosis, Veracyte Inc offers tests for various types of cancer, such as breast cancer, thyroid cancer, and lung cancer. The tests use RNA sequencing to analyze the patient's genetic information and provide a more precise diagnosis. In thyroid diagnostics, Veracyte Inc offers tests for various thyroid diseases that are often difficult to diagnose. The tests help avoid unnecessary surgeries or medical interventions and enable patients to receive a more accurate diagnosis and treatment. In lung diagnostics, Veracyte Inc offers tests for pneumonia, lung cancer, and other lung diseases. The tests use RNA sequencing and imaging to provide accurate diagnoses that help doctors recommend tailored treatment. In addition to these divisions, Veracyte Inc also offers other products and services, such as information campaigns and training for healthcare professionals, as well as support and counseling for patients and their families. Overall, Veracyte Inc aims to revolutionize the medical field and provide patients with better diagnosis and treatment options. The company's tests offer doctors and patients a more precise and personalized diagnosis, allowing for individualized treatment and achieving the best results. Veracyte ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Veracyte's Sales Figures
The sales figures of Veracyte originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Veracyte’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Veracyte's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Veracyte’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Veracyte stock
How much was the turnover of the company Veracyte compared to the previous year?
The revenue of Veracyte has increased by 23.2% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Veracyte?
The revenue of Veracyte is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Veracyte measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Veracyte so important for investors?
The revenue of Veracyte is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Veracyte pay?
Over the past 12 months, Veracyte paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Veracyte is expected to pay a dividend of 0 USD.
What is the dividend yield of Veracyte?
The current dividend yield of Veracyte is .
When does Veracyte pay dividends?
Veracyte pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Veracyte?
Veracyte paid dividends every year for the past 0 years.
What is the dividend of Veracyte?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Veracyte located?
Veracyte is assigned to the 'Health' sector.
Wann musste ich die Aktien von Veracyte kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Veracyte from 11/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/5/2024.
When did Veracyte pay the last dividend?
The last dividend was paid out on 11/5/2024.
What was the dividend of Veracyte in the year 2023?
In the year 2023, Veracyte distributed 0 USD as dividends.
In which currency does Veracyte pay out the dividend?
The dividends of Veracyte are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Veracyte stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Veracyte
Our stock analysis for Veracyte Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Veracyte Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
